Finerenone is a novel non-steroidal mineralocorticoid receptor antagonist. By precisely inhibiting aldosterone- and cortisol-mediated fibrosis and inflammatory responses in the kidneys and cardiovascular system, it provides an innovative therapeutic option for patients with chronic kidney disease (CKD) and specific heart failure (HF).
What Are the Indications for Finerenone?
Chronic Kidney Disease Complicated with Type 2 Diabetes Mellitus
Target Population: Adult patients with CKD complicated by T2DM.
Core Effect: Reduces the risk of a sustained decline in estimated glomerular filtration rate (eGFR) of ≥ 40%.
Delays the progression of end-stage renal disease (which requires dialysis, kidney transplantation, or is defined as a persistent eGFR < 15 mL/min/1.73 m²).
Reduces the composite endpoint events of cardiovascular death, non-fatal myocardial infarction, and heart failure hospitalization.
Heart Failure with Preserved Ejection Fraction
Target Population: Adult heart failure patients with a left ventricular ejection fraction (LVEF) ≥ 40%.
Core Effect: Reduces the risk of cardiovascular death.
Decreases the incidence of heart failure hospitalization and urgent heart failure visits.
Pharmacological Actions
As a non-steroidal mineralocorticoid receptor antagonist, finerenone exerts its effects by selectively blocking the mineralocorticoid receptor.
This receptor is activated by aldosterone and cortisol and participates in the regulation of gene transcription.
Finerenone not only blocks aldosterone-mediated sodium reabsorption but also inhibits the overactivation of mineralocorticoid receptors in both epithelial and non-epithelial tissues. These mechanisms collectively contribute to the suppression of fibrosis and inflammatory processes.
Specifications and Characteristics of Finerenone
10 mg Tablet
Color: Pink.
Markings: Engraved with "FI" on one side and labeled with "10" on the other side.
20 mg Tablet
Color: Yellow.
Markings: Engraved with "FI" on one side and labeled with "20" on the other side.
40 mg Tablet
Color: Gray-orange.
Markings: Engraved with "FI" on one side and labeled with "40" on the other side.
Composition
In addition to the active ingredient finerenone, the tablets contain excipients such as lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, magnesium stearate, and sodium lauryl sulfate.
The film coating consists of hypromellose, titanium dioxide, and talc. The 10 mg and 40 mg formulations are also supplemented with red iron oxide, while the 20 mg and 40 mg formulations contain yellow iron oxide.
Storage Methods for Finerenone
Storage Temperature
Temperature Range: 20°C–25°C (68°F–77°F).
Allowable Fluctuation: 15°C–30°C (59°F–86°F).
Exposure to humid environments must be strictly avoided, and the integrity of the drug packaging must be ensured.
